Recent advancement of immunotherapy targeting lung cancer

As one of the leading cause of deaths in all types of cancer, lung cancer has attracted public attention more than decades. Many chemotherapy and physical surgery therapies have been investigated and applied to lung cancer patients to increase the overall survival rate. As a more recently emerging therapy, immunotherapy is keep advancing in recent years and has achieved great success to complement the traditional therapys weak point and even become the first line treatment against certain types of non-small cell lung cancer (NSCLC). The safety and overall survival improvement of immunotherapy drugs has been tested through multiple cycle of clinical trials, validating their potential for lung cancer treatment. Several clinical trials study the application of immunotherapy singly or in combination with chemotherapy has been established to target lung cancer many years ago. Here, this review will introduce the three most common immunotherapies against lung cancer, and both summarize their application and discuss their recent advancement based on multiple ongoing or finished clinical trials.